Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340594 | 1.00 | GRM5 (0.47) | GRM5UHRF1DYRK1AMAOAKCNQ2 | |
| SCHEMBL16710549 | 0.85 | MAOB (0.51) | MAOA | |
| SCHEMBL28319641 | 0.85 | UHRF1 (0.48) | GRM5UHRF1DYRK1AMAOAKCNQ2 | |
| Hydrochloric Acid SCHEMBL28319637 | 0.83 | GRM5 (0.47) | GRM5UHRF1DYRK1AMAOAKCNQ2 | |
| SCHEMBL23481144 | 0.82 | GRM5 (0.46) | GRM5UHRF1DYRK1AMAOAKCNQ2 | |
| SCHEMBL28056162 | 0.81 | MAOA (0.44) | GRM5DYRK1AMAOALOXLOXL2 | |
| SCHEMBL2118728 | 0.79 | NOS3 (0.64) | GRM5DYRK1AMAOALOXLOXL2 | |
| SCHEMBL29883563 | 0.79 | NOS3 (0.64) | GRM5DYRK1AMAOALOXLOXL2 | |
| SCHEMBL4355540 | 0.78 | UHRF1 (0.54) | GRM5UHRF1DYRK1AKCNQ2LOX | |
| SCHEMBL18415092 | 0.78 | NOS3 (0.47) | GRM5DYRK1AMAOALOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448189-B | Biaryl derivative, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-111886219-B | Immunosuppressant, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-3495358-B1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021262587-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2021-12-30 | — | — | WO | disclosed |
| US-10000480-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-9505748-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| WO-2011059021-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-05-19 | — | — | WO | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| EP-1709037-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LAB (US) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000480-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | GRM5 4110/4885UHRF1 2966/4885DYRK1A 181/4885 |
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | GRM5 3144/4885UHRF1 3070/4885DYRK1A 4858/4885 |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | GRM5 4206/4885UHRF1 3004/4885DYRK1A 4494/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | GRM5 3144/4885UHRF1 3070/4885DYRK1A 4858/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | GRM5 4281/4885UHRF1 4316/4885DYRK1A 4638/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | GRM5 471/4885UHRF1 3348/4885DYRK1A 788/4885 |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | GRM5 4110/4885UHRF1 2966/4885DYRK1A 181/4885 |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | GRM5 1632/4885UHRF1 2963/4885DYRK1A 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.